Tranexamic acid in patients with current or former cancer undergoing hip and knee arthroplasty

Background and objectives: While tranexamic acid (TXA) is an excellent mechanism to reduce blood loss in arthroplasty, its safety in cancer patients-who could potentially benefit the most from blood conservation-is unknown.

Methods: A multicenter, retrospective review of current or former cancer patients undergoing hip/knee arthroplasty from 2014 to 2019 was performed. The use of intravenous TXA, indication (oncologic/degenerative), cancer state, cancer type, surgical factors, demographics, and comorbidities were collected. The association between TXA use and 90-day/1-year complications was analyzed with multivariable logistic regressions.

Results: We identified 282 patients with current (87.9%) or former (12.1%) malignancies undergoing arthroplasty (73.0% oncologic/27.0% degenerative). About 74 (26.2%) patients received TXA (52.7% had oncologic indications, 74.3% had active cancer). In adjusted analysis, TXA was not associated with increased risk of venous thromboembolism within 90-days (odds ratio [OR] 0.59; 95% confidence interval [CI] 0.16-2.16, p = 0.43) or 1-year (OR 0.47; 95%CI 0.15-1.44, p = 0.19), with a trend towards lower risk. Similar results were seen for mortality and wound complications, and when stratifying by indication.

Conclusion: TXA was not associated with increased complications in current or former cancer patients undergoing arthroplasty. Future randomized studies of TXA in arthroplasty should include cancer patients; in the interim, clinicians should weigh the theoretical risks of TXA with the known benefits of reduced blood loss in oncology patients.